amiridine and Brain-Ischemia

Clinical, neuropsychological and neurophysiological examination was performed in 53 patients, aged 33-75 years, in the early rehabilitation period of the first hemispheric ischemic stroke. Cognitive functions were measured with the MMSE, the FAB, the Clock Drawing Test, the 5-Word test, the Schulte probe, verbal fluency test, etc. Cognitive evoked potentials were recorded in 30 patients. Examination was carried out a month after the stroke and after 2 months of therapy with neuromidin (ipidacrinum). The control group consisted of 37 people without stroke in the case history. The statistically significant decrease of cognitive functions in comparison with control group was revealed at the first visit. The statistically significant regression of cognitive deficit, with the most distinct positive dynamics of frontal functions and semantic verbal fluency, was identified as a result of the treatment. The significant improvement in cognitive evoked potentials in the form of the reduction of P3 latency was recorded after the treatment.

Topics: Adult; Aged; Aminoquinolines; Brain Ischemia; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Electroencephalography; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Middle Aged; Neuropsychological Tests; Time Factors; Treatment Outcome

An aim of the study was to evaluate the therapeutic effect of neyromidin in patients with ischemic stroke. Forty patients with acute carotid artery stroke were enrolled into the study. The diagnosis was made on the basis of general clinical methods as well as the neurological examination, CT or MRI scans of the head, investigation of hemodynamic parameters, ECG, ultrasound dopplerography of major brain arteries. Neurological deficit was measured using the Scandinavian Scale. According to the TOAST classification, 14 (35%) of the patients suffered from large vessel disease, 16 (40%) patients were diagnosed with cardioembolic disease and 10 (25%) with the small vessel disease. Patients were randomized to the study and control groups (n=20 patients). All patients received standard treatment. Patients of the study group were treated with neyromidin. The study duration was 80 days. Clinical examinations were performed in the acute phase, on 21st and 80th days after stroke. Better recovery of neurological functions was identified in patients treated with neyromidin compared to control patients. No side-effects of neyromidin was found. Neyromidin is recommended for complex treatment of patients in the acute stage of ischemic stroke of carotid origin.

Topics: Administration, Ophthalmic; Aged; Aminoquinolines; Brain Ischemia; Dose-Response Relationship, Drug; Electrocardiography; Female; Hemodynamics; Humans; Injections, Intramuscular; Magnetic Resonance Imaging; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome

Authors have studied the efficacy of adaptol and neyromidin in the combined treatment of patients with chronic cerebral circulation insufficiency and consequences of closed head injury using neurophysiological monitoring which included dynamic evaluation of central conductivity, neuropsychological tests and analysis of blood BDNF levels. Severe autonomic disorders, anxiety and low level of learning observed in all patients are correlated with neurophysiological (increased central conductivity time) and neurotrophic (decreased blood BDNF levels) profiles. These indicators may change throughout the treatment. The combination of adaptol and neyromidin enhanced greatly the efficacy of combined treatment. The received data allow recommending neurophysiological monitoring for treatment optimization of numerous neurological diseases that demand neuroplasticity stimulation.

Topics: Adolescent; Adult; Aged; Aminoquinolines; Anxiety; Biureas; Brain Injuries; Brain Ischemia; Brain Waves; Brain-Derived Neurotrophic Factor; Drug Therapy, Combination; Female; Humans; Learning; Male; Middle Aged; Neuronal Plasticity; Neuropsychological Tests; Treatment Outcome

Topics: Aged; Aminoquinolines; Brain Ischemia; Cholinesterase Inhibitors; Chronic Disease; Female; Humans; Male; Treatment Outcome

The efficacy of neyromidin in the treatment of motor disturbances after ischemic stroke (IS) was studied. The study included 60 patients with left middle cerebral artery stroke. The diagnosis was made on the basis of general clinical methods as well as the neurological examination, computed tomography (CT) scan of the head, investigation of hemodinamic parameters, ECG, ultrasound dopplerography of main head arteries, biochemical blood tests. Patients were divided into two equal groups: patients in the acute phase of stroke (main group) and patients in the early rehabilitation phase (comparison group). The groups were matched for sex, age, clinical features of the disease. Neyromidin was administered for 60 days. After the completion of the treatment with neyromidin, an improvement of the neurological status as well as an enhancement of motor functions in patients with moderate and severe paresis of the leg were observed in 30 patients with acute ischemic stroke.

Topics: Aged; Aminoquinolines; Brain Ischemia; Female; Follow-Up Studies; Humans; Male; Middle Aged; Motor Activity; Recovery of Function; Treatment Outcome